Price movement over the last 24 hours
ADMA Biologics Inc vs iShares MSCI Singapore ETF — how do they compare? ADMA Biologics Inc trades at $9.06 (market cap $2.13B), while iShares MSCI Singapore ETF trades at $31.06. The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWS | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $30.66 |
52-Week Low | $7.60 | $26.08 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EWS, the iShares MSCI Singapore ETF, trades at $30.28, up 0.4% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF offers a 3.97% dividend yield and is approaching its 2007 all-time high of $31.94, supported by Singapore's economic stability and financial sector strength. Recent news highlights focus on Singapore's AI initiatives and property market activity.
The outlook for EWS is positive, with potential upside to the $31.94 resistance level, but risks include concentrated holdings in financials and regional economic sensitivity. Investor sentiment is mixed, with some analysts advocating for diversification benefits while others caution on valuation after recent gains.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →